

Applicant: Robert E. ~~Ramer~~, et al.
U.S. Serial No.: 09/934,773
Filed: August 21, 2001
Page 5

In the claims:

In compliance with 37 C.F.R. §1.121 for making amendments, Applicants present all pending claims with status indicators.

Please amend the claims 53, 87 and 97 as follows:

--1 to 52. Canceled. --

(C7) --53. (Currently amended) A monoclonal antibody which specifically binds to the epitope bound by ~~a the monoclonal antibody designated 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, produced by any one of the hybridomas designated HB-12612, HB-12613, HB-12614, HB-12616, HB-12618, HB-12615, or HB-12617, respectively, as deposited with the American Type Culture Collection.~~ --

--54 TO 55. Canceled. --

--56. (Previously presented) The monoclonal antibody of claim 53 which is a chimeric antibody.--

--57. (Previously presented) The monoclonal antibody of claim 56, wherein the chimeric antibody is a humanized antibody.—

--58. (Previously presented) A cell that produces the monoclonal antibody of claim 53.-

--59. (Previously presented) A recombinant protein comprising the antigen binding region of the monoclonal antibody of claim 53.--

--60. (Previously presented) An Fab, F(ab')2 or Fv fragment of the monoclonal antibody of claim 53.--

Applicant: Robert E. K. [REDACTED], et al.
U.S. Serial No.: 09/934,773
Filed: August 21, 2001
Page 6

- 61. (Previously presented) An immunoconjugate comprising a cytotoxic agent and the monoclonal antibody of claim 53.--
- 62. (Previously presented) An immunoconjugate comprising a cytotoxic agent and the recombinant protein of claim 59.--
- 63 to 86. Canceled. --
- 87. (Currently amended) A composition, comprising ~~an pharmaceutically effective amount of the antibody of claim 53 that specifically binds to the extracellular domain of SEQ ID NO.: 2, and a pharmaceutically acceptable carrier.~~--
- 88. (Previously presented) A kit comprising the monoclonal antibody of claim 53 and a detectable label.--
- 89. (Previously presented) A monoclonal antibody of claim 53 which specifically binds to the epitope bound by the monoclonal antibody designated 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, such that the antibody competitively inhibits the immunospecific binding of any of the monoclonal antibodies designated 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, respectively, to PSCA of SEQ ID NO: 2.--
- 90. (Previously presented) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 1G8, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 1G8 to PSCA of SEQ ID NO: 2.--
- 91. (Previously presented) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 2A2, wherein

Applicant: Robert E. ~~Rader~~, et al.

U.S. Serial No.: 09/934,773

Filed: August 21, 2001

Page 7

the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 2A2 to PSCA of SEQ ID NO: 2.--

- 92. (Previously presented) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 2H9, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 2H9 to PSCA of SEQ ID NO: 2.--
- 93. (Previously presented) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 3C5, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3C5 to PSCA of SEQ ID NO: 2.--
- 94. (Previously presented) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 3E6, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3E6 to PSCA of SEQ ID NO: 2.--
- 95. (Previously presented) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 3G3, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3G3 to PSCA of SEQ ID NO: 2.--
- 96. (Previously presented) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 4A10, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 4A10 to PSCA of SEQ ID NO: 2.--
- 97. (Currently amended) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by a the monoclonal antibody designated 1G8, 2A2, 2H9,

Applicant: Robert E. **R**uder, et al.

U.S. Serial No.: 09/934,773

Filed: August 21, 2001

Page 8

3C5, 3E6, 3G3 or 4A10, produced by any one of the hybridomas designated HB-12612, HB-12613, HB-12614, HB-12616, HB-12615, HB-12618, or HB-12617, respectively, as deposited with the American Type Culture Collection. --

- 98. (Previously presented) A monoclonal antibody which immunospecifically binds the epitope bound by the monoclonal antibody designated 2A2 or 3G3, produced by the hybridomas designated HB-12613, or HB-12615, respectively, as deposited with the American Type Culture Collection.--
- 99. (Previously presented) A monoclonal antibody which specifically recognizes and binds a portion of a PSCA of SEQ ID. NO. 2, wherein the portion is selected from the group consisting of:
 - a. amino acid residues 2 through 50 as described in SEQ ID NO: 2;
 - b. amino acid residues 85 through 123 as described in SEQ ID NO: 2;
 - c. amino acid residues 46 through 109 as described in SEQ ID NO: 2;
 - d. amino acid residues 18 through 98 as described in SEQ ID NO: 2;.
 - e. amino acid residues 22 through 99 as described in SEQ ID NO: 2;
 - f. amino acid residues 21 through 50 as described in SEQ ID NO: 2;
 - g. amino acid residues 46 through 85 as described in SEQ ID NO: 2;
 - h. amino acid residues 50 through 64 as described in SEQ ID NO: 2;
 - i. amino acid residues 67 through 81 as described in SEQ ID NO: 2;
 - j. amino acid residues 21 through 99 as described in SEQ ID NO: 2;
 - k. amino acid residues 71 through 82 as described in SEQ ID NO: 2;
 - l. amino acid residues 85 through 99 as described in SEQ ID NO: 2;
 - m. amino acid residues 18 through 50 as described in SEQ ID NO: 2;
 - n. amino acid residues 46 through 98 as described in SEQ ID NO: 2; or
 - o. amino acid residues 85 through 98 as described in SEQ ID NO: 2.--